Renaissance Technologies
EPRS

Renaissance Technologies’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Renaissance Technologies’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,056
Closed -$135K – 3602
2015
Q1 		$135K Sell
15,056
-20,880
-58% -$168K ﹤0.01% 2970
2014
Q4 		$204K Buy
+35,936
New +$188K ﹤0.01% 2692

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Renaissance Technologies's EPRS Position: Q2 2015 in Review

Renaissance Technologies sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2015, closing a stake of 15,056 shares — an estimated $135K sold.

Renaissance Technologies first reported a position in EPRS in Q4 2014 and held it in 2 quarters. The position peaked at $204K in Q4 2014. 41 funds tracked by Wall St. Rank hold EPRS as of Q2 2015.

  • Renaissance Technologies reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2015 after selling out during the quarter.
  • Renaissance Technologies sold 15,056 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2015, an estimated $135K.
  • Renaissance Technologies first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 2 quarters.
  • Renaissance Technologies's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $204K in Q4 2014.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2015.

Based on Renaissance Technologies's 13F filing for Q2 2015, filed 14 Aug 2015.